BluePath Capital Management’s Gilead Sciences GILD Stock Holding History

BluePath Capital Management’s Portfolio GILD Stock Details GILD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.13M	Buy	8,912 +366	+4%	+$48.2K	0.62%	66
2026 Q1	$1.19M	Buy	8,546 +2	+0%	+$280	0.82%	38
2025 Q4	$1.05M	Buy	8,544 +1,098	+15%	+$133K	0.71%	60
2025 Q3	$827K	Buy	7,446 +1,809	+32%	+$206K	0.6%	66
2025 Q2	$625K	Buy	5,637 +939	+20%	+$99.9K	0.55%	66
2025 Q1	$526K	Sell	4,698 -5,156	-52%	-$532K	0.55%	61
2024 Q4	$886K	Buy	9,854 +1,299	+15%	+$117K	0.48%	57
2024 Q3	$717K	Sell	8,555 -1,745	-17%	-$133K	0.44%	63
2024 Q2	$707K	Buy	10,300 +2,960	+40%	+$198K	0.5%	55
2024 Q1	$538K	Buy	7,340 +220	+3%	+$16.9K	0.41%	62
2023 Q4	$602K	Buy	7,120 +928	+15%	+$72.2K	0.51%	40
2023 Q3	$464K	Buy	+6,192	New	+$476K	0.43%	43

Other funds holding GILD

LMFP

Larry Mathis Financial Planning Phoenix, Arizona $124B AUM

Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

New York State Teachers Retirement System (NYSTRS) Albany, New York $54.2B AUM 43.77% 1-Year Est. Return

Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return

Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return

CIM

Confluence Investment Management St. Louis, Missouri $6.4B AUM 9.79% 1-Year Est. Return

ATO

Alecta Tjanstepension Omsesidigt Stockholm, Sweden $23.8B AUM 34.25% 1-Year Est. Return

CGH

Crossmark Global Holdings Houston, Texas $7.71B AUM 37.66% 1-Year Est. Return

BluePath Capital Management's GILD Position: Q2 2026 in Review

BluePath Capital Management increased its Gilead Sciences (GILD) stake by 4.3% in Q2 2026, buying an estimated $48.2K and bringing the position to 8,912 shares worth $1.13M. The position accounts for 0.62% of the portfolio, ranked #66.

BluePath Capital Management first reported a position in GILD in Q3 2023 and has held it in 12 quarters since. The position peaked at $1.19M in Q1 2026. 690 funds tracked by Wall St. Rank hold GILD as of Q2 2026.

BluePath Capital Management held 8,912 shares of Gilead Sciences worth $1.13M as of Q2 2026.
BluePath Capital Management bought 366 Gilead Sciences shares in Q2 2026, an estimated $48.2K.
Gilead Sciences made up 0.62% of BluePath Capital Management's portfolio in Q2 2026, its #66 holding.
BluePath Capital Management first reported a position in Gilead Sciences in Q3 2023 and has held it in 12 quarters since.
BluePath Capital Management's Gilead Sciences position peaked at $1.19M in Q1 2026.
690 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2026.

Based on BluePath Capital Management's 13F filing for Q2 2026, filed 24 Jul 2026.